Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > Resource hub > Why we need to rethink T1D care in older age
“When people talk about type 1 diabetes (T1D) technology, the focus is often on young people or those newly diagnosed with T1D. Yet one of the most important conversations we need to have is what happens as people grow older with type 1, especially when they develop additional health needs or become reliant on others for their care.
Over the past few years, I’ve been involved in introducing hybrid closed loop (HCL) technology to some of our most complex patients; people with complex care requirements, learning disabilities, frailty, and people living with advanced dementia. What we’ve learned is simple: we should never assume that technology isn’t suitable for someone because they are older or have complex care needs.
Too often, healthcare focuses on fixing a problem rather than understanding an individual. My approach has always been to ask: what’s happening in this person’s life, what matters to them, and how can we make things work around them?
That philosophy shaped our approach when we began introducing HCL to people who, historically, might never have been considered for it. Many were receiving insulin support from district nursing teams. Some had highly unpredictable glucose levels, resulting in frequent interventions and hospital admissions. On paper they were eligible for technology, but the assumption was often that it would be too difficult to implement. We discovered the opposite is often true.
One of the first people we onboarded onto HCL was an older gentleman who had complex care needs. He had extremely unstable glucose levels and required significant nursing input. Since starting on the system, his glucose levels have become far more predictable and both his health and quality of life have improved dramatically. His district nurses describe him as “a new man”.
In turn, this significantly improved care efficiency for the nursing team.
Previously, nurses would visit the gentleman in the morning and find his glucose levels dangerously low or extremely high. Either situation would trigger additional visits and unplanned workload. With HCL, glucose levels became much more stable, reducing the need for repeated interventions throughout the day. The result has been less stress Previously, nurses would visit the gentleman in the morning and find his glucose levels dangerously low or extremely high. Either situation would trigger additional visits and unplanned workload. With HCL, glucose levels became much more stable, reducing the need for repeated interventions throughout the day. The result has been less stress and unexpected workload for staff and, most importantly, a better experience for the patient.
Of course, technology isn’t right for everyone. A lot of older people simply don’t want it, and that’s okay. Nobody should feel pressured into using technology because someone else thinks it’s the right thing to do. Instead, we should create opportunities for people to try it and make an informed decision for themselves. We’ve learned that building relationships, providing support and working together to address concerns is essential.
Currently in the UK, there are about 14,400 people aged 80 and over living with T1D. Better treatments, improved care and advances in technology mean people are living longer than ever before. That’s something to celebrate. It also means we must think carefully about how we support people as they age.
One of the biggest challenges I see is that as people age, they become focused on trying to control levels by eating less, rather than adjusting management appropriately. Over time this can contribute to malnutrition, loss of muscle mass and increased frailty.
This is where technology can help. HCL can absorb some of the variability that comes with everyday life. The tech can help manage things like a piece of cake, extra roast potatoes at Sunday lunch or changes in routine in a way that traditional insulin approaches often struggle to accommodate.
My hope is that where someone lives or the support they receive will never become a barrier to accessing T1D technology.
The goal isn’t for everyone to have the same experience but the same opportunity. Whether someone lives independently or resides in a care home, they should be able to access technology if it could benefit them.
The future of type 1 care isn’t only about helping people live longer. It’s about helping them live well.”
Retired accountant Andy Buckle has lived with type 1 diabetes for almost five decades. After a demanding career, he began to think about how he could contribute something meaningful.
Alexandra shares how a sudden diagnosis of advanced diabetic retinopathy threatened her sight, how swift treatment helped protect her vision, and why she wants others with type 1 diabetes to know that even in the hardest moments, there is hope.
Meet the Psoriasis Association, the latest member of our innovative, cross-disciplinary autoimmune research initiative, Connect Immune Research.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?